Market Overview

UPDATE: Wedbush Securities Reiterates Outperform Rating, Raises PT on Synageva BioPharma Corp.

Related GEVA
Synageva Shares Tumble Amid Positive Phase 3 Data, A Director's 75% Gain & Analyst Concerns
Dow Flirts With 17,000, S&P 500 Inches Closer To 2,000 In First Trading Day Of The Third Quarter

In a report published Wednesday, Wedbush Securities reiterated its Outperform rating on Synageva BioPharma Corp. (NASDAQ: GEVA), and raised its price target from $42.00 to $50.00.

Wedbush Securities noted, “In an abstract at AALSD, the company reported that in 3 of 7 subjects where MRI data were available, there was a reduction in liver fat fractions, indicating that, in addition to normalization of liver enzymes and lipids, patients could be seeing additional clinical benefit with SBC-102 treatment. We expect updates to these data as they become available at AALSD and LDN (Q1:13).”

Synageva BioPharma Corp. closed on Tuesday at $42.85.

Posted-In: Wedbush SecuritiesAnalyst Color Price Target Reiteration Analyst Ratings

 

Most Popular

Related Articles (GEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters